PFND

Pathfinder Cell Therapy, Inc. [PFND] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

PFND Stock Summary

Top 10 Correlated Stocks

PFND

In the News

PFND Financial details

Company Rating
-
Market Cap
20.01K
Income
-1.39M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
1
Optionable
No
Shortable
Yes
Earnings
-
P/E
0
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
-
P/FCF
-0.02
Quick Ratio
-
Current Ratio
0.01
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0
EPS next Y
-
EPS next Q
-
EPS this Y
-7.41%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-11.09%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
50%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-1575%
ROE
32%
ROC
0.19%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.0E-6-1.0E-4
52W High
-
52W Low
-
RSI
-
Rel Volume
2.63
Avg Volume
190
Volume
500
Perf Week
0%
Perf Month
0%
Perf Quarter
0%
Perf Half Y
0%
-
-
-
-
Beta
-23.008
-
-
Volatility
0%, 0%
Prev Close
0%
Price
0.0001
Change
9900%

Something similar

Top by Market Cap
VOO
ABEA.DE
TSLA
BRK-B
JPM
Same Sector
ADVM
GKOS
MSON
ICCT
GTMS.TO
Top Correlated Stocks
MICR
SOFO
ABMT
ABTI
ACBM
Similar Market Cap
WTNW
GLRI
RETC
PFND
ENTI

Company Profile

Healthcare Biotechnology

Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.